The short interest in Codexis (NASDAQ:CDXS) has declined from 536,828 on May 31,2016 to 522,540 on June 15,2016. The change was measured at 14,288 shares or 2.7%. The leftover shorts were 1.8% of the floated shares. The days to cover are 3, given the average daily volume of 162,903 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Codexis (NASDAQ:CDXS): The stock opened at $4.06 on Friday but the bulls could not build on the opening and the stock topped out at $4.25 for the day. The stock traded down to $3.97 during the day, due to lack of any buying support eventually closed down at $4.17 with a loss of -0.95% for the day. The stock had closed at $4.21 on the previous day. The total traded volume was 3,245,625 shares.
The company shares have rallied 5.84% from its 1 Year high price. On Aug 11, 2015, the shares registered one year high at $4.62 and the one year low was seen on Mar 22, 2016. The 50-Day Moving Average price is $3.84 and the 200 Day Moving Average price is recorded at $3.78.
Codexis (NASDAQ:CDXS) has tumbled 0.24% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 2.96% in the last four weeks. In the past week, the company has outperformed the S&P 500 by 1.42% and the outperformance has advanced to 6.08% for the last 4 weeks period.
Codexis, Inc. is a developer of biocatalysts. The Company is engaged in the pharmaceutical and fine chemical industries. The Companys CodeEvolver protein engineering technology platform is used in the evolution and optimization of biocatalysts to perform specific and desired chemical reactions at commercial scale. The pharmaceutical customers use its technology, products and services in their manufacturing process development and production of drugs. The Companys technologies enable scale-up and implementation of biocatalytic solutions for sustainable process development, from research to manufacturing. The Companys products include Codex screening panels and kits that enable customers to establish optimal reactions. The Companys pharmaceutical products include enzymes, pharmaceutical intermediates and Codex Biocatalyst Kits and Panels.